Nuvation Bio Inc. (NYSE: NUVB)
Health Care · Pharmaceuticals · US
$4.90
-2.00% today · +35.9% 1Y
Nuvation Bio Inc. (NYSE: NUVB) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.76B and employs 305 people.
Over the last twelve months the share price has gained 35.9%, trading between 3.36 and 9.75.
Tweenvest scores Nuvation Bio Inc. across four factors: quality 39/100, value 70/100. Its strongest factor is value.
NUVB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.76B
- Revenue (TTM)
- $169.90M
- P/E
- —
- EPS
- -0.44
- Dividend yield
- —
- Beta (5Y)
- 1.62
- 52-week high
- $9.75
- 52-week low
- $3.36
- Avg volume (3M)
- —
- Shares outstanding
- 351.12M
- Employees
- 305
- Next earnings
- —
About Nuvation Bio Inc.
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
- ISIN
- US67080N1019
- Founded
- 2018
- Listed since
- Aug 26, 2020
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Neuren Pharmaceuticals LimitedASX: NEU | $1.79B | AU$20.20 | -0.39% |
| Zhejiang Medicine Co., Ltd.SHSE: 600216 | $1.78B | CN¥12.59 | +1.29% |
| Tsumura & Co.TSE: 4540 | $1.78B | ¥3,772.00 | +1.86% |
| PharmaBlock Sciences (Nanjing), Inc.SZSE: 300725 | $1.77B | CN¥51.01 | -7.84% |
| Cohance Lifesciences LimitedNSEI: COHANCE | $1.74B | Rs441.00 | -2.28% |
| Shanghai Shyndec Pharmaceutical Co., Ltd.SHSE: 600420 | $1.70B | CN¥8.51 | +1.43% |
| Faes Farma, S.A.BME: FAE | $1.69B | €4.91 | +1.24% |
| Alivus Life Sciences LimitedNSEI: ALIVUS | $1.68B | Rs1,326.30 | -3.49% |
Figures last refreshed Oct 11, 2026.